SRP-4045 + SRP-4053 (ESSENCE)

September 25, 2026: Sarepta Therapeutics (NASDAQ: SRPT) said it will present new Duchenne muscular dystrophy data at the 31st Annual Congress of the World Muscle Society in Hiroshima, Sept. 29-Oct. 3, 2026.

Delandistrogene moxeparvovec (ELEVIDYS): a late-breaking poster on Sept. 30 will report efficacy and safety in older ambulatory Duchenne patients aged 8-12 years at treatment. Additional Sept. 30 posters will cover functional and safety outcomes up to 3 years post-infusion in the EMBARK study, micro-dystrophin expression and safety in 2-3-year-olds in the ENDEAVOR and ENVOL studies, and a pooled safety analysis across Phase 1 to Phase 3 trials. A preclinical poster will present efficacy and safety of early intervention in DMD MDX mice.

Golodirsen and casimersen: Sarepta will also present Sept. 30 ESSENCE Phase 3 results and a post hoc analysis comparing golodirsen and casimersen with placebo in Duchenne muscular dystrophy.

The announced catalyst is the upcoming WMS 2026 data presentation; the release does not disclose the study results themselves.